Clofarabine monotherapy in two patients with refractory Langerhans cell histiocytosis

Masahiro Irie, Tomohiro Nakano, Saori Katayama, Tasuku Suzuki, Kunihiko Moriya, Yuko Watanabe, Nobu Suzuki, Yuka Saitoh-Nanjyo, Masaei Onuma, Takeshi Rikiishi, Hidetaka Niizuma, Yoji Sasahara, Shigeo Kure

Research output: Contribution to journalArticlepeer-review

Abstract

Background: Better therapeutic options other than conventional chemotherapy for pediatric patients with refractory Langerhans cell histiocytosis (LCH) remain undetermined. Case: We successfully treated two patients with refractory and risk organ negative LCH with clofarabine (CLO) monotherapy after recurrence. We administered total 23 courses of CLO monotherapy in patient 1 and 4 courses in patient 2. Both patients had distinct clinical manifestations but achieved a durable complete response with acceptable adverse effects of transient myelosuppression. CLO monotherapy was still effective when he had the second recurrent lesion after first completion of CLO in patient 1. We could discontinue prednisolone to control his refractory inflammation of LCH after completing CLO chemotherapy in patient 2. Conclusion: Although large-scale studies are warranted, CLO monotherapy could be a therapeutic option for high efficacy and feasibility besides other intensive combination chemotherapies or allogeneic hematopoietic stem cell transplantation for refractory LCH without risk organ involvement in children.

Original languageEnglish
JournalCancer Reports
DOIs
Publication statusAccepted/In press - 2021

Keywords

  • allogeneic hematopoietic stem cell transplantation
  • cladribine
  • clofarabine
  • high dose-cytarabine
  • refractory Langerhans cell histiocytosis

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Clofarabine monotherapy in two patients with refractory Langerhans cell histiocytosis'. Together they form a unique fingerprint.

Cite this